Supplement

You have full text access to this OnlineOpen article

Effective but cost-prohibitive drugs in breast cancer treatment†‡

A clinician's perspective

  1. Jose Bines MD1,§,¶,*,
  2. Alexandru Eniu MD2

Article first published online: 3 OCT 2008

DOI: 10.1002/cncr.23837

Issue

Cancer

Cancer

Supplement: Guidelines for International Breast Health and Cancer Control–Implementation

Volume 113, Issue Supplement 8, pages 2353–2358, 15 October 2008

Additional Information

How to Cite

Bines, J. and Eniu, A. (2008), Effective but cost-prohibitive drugs in breast cancer treatment. Cancer, 113: 2353–2358. doi: 10.1002/cncr.23837

Author Information

  1. 1

    Instituto Nacional de Cancer, Rio de Janeiro, Brazil

  2. 2

    Department of Breast Tumors, Cancer Institute “Ion Chiricuta,” Cluj-Napoca, Romania

  1. §

    Dr. Bines has received honoraria from Astra-Zeneca and has acted as either a consultant or in an advisory role for Bristol Myers-Squibb and Astra-Zeneca.

  2. Fax: (011) 55-21-2577-6941

*Instituto Nacional de Cancer-Brasil, Rua Visconde de Santa Isabel 274, Rio de Janeiro, Brasil

  1. †

    The views expressed in this article are the results of independent work and do not represent the views of the authors' institutions.

  2. ‡

    Complete financial disclosures are presented at the end of this article.

Publication History

  1. Issue published online: 3 OCT 2008
  2. Article first published online: 3 OCT 2008
  3. Manuscript Accepted: 24 JUN 2008
  4. Manuscript Received: 10 JUN 2008

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (161K)

REFERENCES

  • 1
    Peto R,Boreham J,Clarke M,Davies C,Beral V. UK and USA breast cancer deaths down 25% in year 2000 at ages 20–69 years [letter]. Lancet. 2000; 355: 1822.
  • 2
    Ministry of Health of Brazil. National Cancer Institute Annual Report. Rio de Janeiro, Brazil: Ministry of Health of Brazil; 2002.
  • 3
    Berry DA,Cronin KA,Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005; 353: 1784–1792.
  • 4
    Kaufmann M,Jonat W,Hilfrich J, et al. Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 study. J Clin Oncol. 2007; 25: 2664–2670.
  • 5
    Henderson IC,Berry DA,Demetri GD, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003; 21: 976–983.
  • 6
    Roche H,Fumoleau P,Spielmann M, et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 trial. J Clin Oncol. 2006; 24: 5664–5671.
  • 7
    Martin M,Pienkowski T,Mackey J, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med. 2005; 352: 2302–2313.
  • 8
    Smith I,Procter M,Gelber RD, et al. 2-Year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet. 2007; 369: 29–36.
  • 9
    Perez EA,Romond EH,Suman VJ, et al. Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer [abstract]. ASCO Annual Meeting Proceedings. J Clin Oncol. 2007; 25: 18S. Abstract 512.
  • 10
    Robert NJ,Eiermann W,Pienkowski T, et al. BCIRG 006: docetaxel and trastuzumab-based regimens improve DFS and OS over AC-T in node positive and high risk node negative HER2 positive early breast cancer patients: quality of life (QOL) at 36 months follow-up [abstract]. ASCO Annual Meeting Proceedings. J Clin Oncol. 2007; 25: 18S. Abstract 19647.
  • 11
    Steinbrook R. Closing the affordability gap for drugs in low-income countries. N Engl J Med. 2007; 357: 1996–1999.
  • 12
    Schechter CB. Cost effectiveness in context. J Clin Oncol. 2007; 25: 609–610.
  • 13
    Woo PPS,Kim JJ,Leung GM. What is the most cost-effective population based cancer screening package for Chinese women? J Clin Oncol. 2007; 25: 617–624.
  • 14
    Telli ML,Hunt SA,Carlson RW,Guardino AE. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J Clin Oncol. 2007; 25: 3525–3533.
  • 15
    Slamon DJ,Clark GM,Wong SG,Levin W,Ullrich A,McGuire W. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235: 177–182.
  • 16
    Joensuu H,Kellokumpu-Lehtinen PL,Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 2006; 354: 809–820.
  • 17
    National Institutes of Health. Trastuzumab for 6 months or 1 year in treating women with nonmetastatic breast cancer that can be removed by surgery. Clinical trials no. NCT00381901. Bethesda, Md: National Institutes of Health; 2007. Available at:http://clinicaltrials.gov/show/NCT00381901. Accessed on March 13, 2008.
  • 18
    Colleoni M,Maibach R. BIG 1-07/1BCSG 35-07 SOLE Ready for Activation. Breast International Group Newsletter. 2007; 9: 22.
  • 19
    Ratain M,Cohen EE. The value meal: how to save $1700 per month or more on lapatinib. J Clin Oncol. 2007; 25: 3397–3398.
  • 20
    Pegram MD,Pietras R,Bajamonde A, et al. Targeted therapy: wave of the future. J Clin Oncol. 2005; 23: 1776–1781.
  • 21
    Sledge GWJr. What is targeted therapy? J Clin Oncol. 2005; 23: 1614–15.
  • 22
    Paik S,Tang G,Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006; 24: 3726–3734.
  • 23
    Goetz MP,Knox SK,Suman VJ, et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat. 2007; 101: 113–121.
  • 24
    Pegram M,Hsu S,Lewis G, et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene. 1999; 13: 2241–2251.
  • 25
    Garber JE,Richardson A,Harris LN, et al. Neo-adjuvant cisplatin (CDDP) in “triple-negative” breast cancer (BC). Presented at the 29th Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, December 14–17, 2006. Abstract 3074.
  • 26
    Colleoni M,Rocca A,Sandri MT, et al. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol. 2002; 13: 73–80.
  • 27
    Burstein HJ,Spigel D,Kindsvogel K, et al. Metronomic chemotherapy with and without bevacizumab for advanced breast cancer: a randomized phase II study. Presented at the 28th Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, December 8–11, 2005. Abstract 4.
  • 28
    National Institutes of Health. Combination chemotherapy after surgery in treating patients with stage I, stage II, or stage III breast cancer. Clinical trials no. NCT00022516. Bethesda, Md: National Institutes of Health; 2007. Available at: http://clinicaltrials.gov/ct2/show/NCT00022516?term=ibcsg+22&rank=1. Accessed on March 13, 2008.
  • 29
    Branco LP,Dienstmann R,Bines J. Megestrol acetate after aromatase inhibitor failure in metastatic breast cancer [abstract]. ASCO Annual Meeting Proceedings. J Clin Oncol. 2006; 24. Abstract 10572.
  • 30
    Lewis JS,Meeke K,Osipo C. Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation. J Natl Cancer Inst. 2005; 23: 1746–1759.
  • 31
    Blackman DJ,Masi CM. Racial and ethnic disparities in breast cancer mortality: are we doing enough to address the root causes? J Clin Oncol. 2006; 24: 2170–2178.
View Full Article (HTML) Get PDF (161K)